Clinical TrialJun 17, 2026, 09:01 AM
Connect Biopharma Completes Enrollment in Phase 2 Asthma Study
AI Summary
Connect Biopharma Holdings Ltd announced the completion of enrollment in its Phase 2 Seabreeze STAT Asthma study evaluating rademikibart for acute exacerbations in asthma patients. The company is also on track to complete enrollment in its Seabreeze STAT COPD study this month and anticipates reporting topline data from the Asthma study in early September 2026. Connect Biopharma maintains a strong balance sheet with a cash runway into the second half of 2027 and is eligible for up to $110 million in milestone payments from its Simcere license.
Key Highlights
- Completed enrollment in Phase 2 Seabreeze STAT Asthma study with 160 participants.
- On track to complete enrollment in Phase 2 Seabreeze STAT COPD study with 160 participants this month.
- Expects topline data from Seabreeze STAT Asthma study in early September 2026.
- Cash runway extends into 2H 2027.
- Eligible for up to $110 million in remaining milestone payments from Simcere license.
Price Impact
More from CNTB